recently tested in SCD. 1, 3 The joint experience of the authors of this study with the oxygenscan has prompted us to study methodological aspects and pre-analytical factors that could influence key oxygenscan parameters. A better understanding of these aspects and factors will strongly enhance reproducibility of results and will enable interlaboratory comparison of results and collaboration.
The Our results show that 24 hours of blood storage (4°C) compared to 4 hours of storage (at room temperature) significantly increased the EImax ( Figure 1A) . EImax also increased significantly with a lower camera gain ( Figure 1G ). Although the effect was less pronounced, together, this indicates that deformability measured during normoxia is influenced by the age of the sample as well as the height of the diffraction pattern.
EImin was significantly increased when less RBCs were used for the measurement ( Figure 1F ) and when PI control was switched on ( Figure 1L ). Together, this indicates that deformability under hypoxic conditions is dependent on the amount of RBCs used for measurements, and the speed at which deoxygenation occurs.
The PoS was only significantly affected by the amount of RBCs used, in a sense that a lower number of RBCs was associated with a lower oxygen concentration at which RBCs start to sickle (ie, PoS; Figure 1E ). We also noted that methodological factors, that is, the cam- The present study clearly shows that key oxygenscan parameters (EImax, PoS and EImin) are dependent on methodological aspects and pre-analytical conditions. As a consequence, intra-and betweenlaboratories comparisons imply the need for standardization. Therefore, we believe that each laboratory using this technique should perform oxygenscan measurements in a standardized way.
The degree of anemia is highly variable in SCD. Some patients have a hematocrit lower than 20%, while others (Hemoglobin SC patients) have mild-to-moderate anemia. We recommend performing an RBC count prior to oxygenscan measurements to standardize the amount of RBCs used. An RBC count of 40*10 6 /mL, for example, ensures that a sufficient amount of RBCs will be present in the couette system of the Lorrca, to render a reliable high quality diffraction pattern. Another pre-analytical aspect is the time between collecting a sample and performing the actual measurement. Several laboratories are not able to perform measurements within 4 hours due to shipping time. Since the time between blood sampling and analysis affects EImax, we recommend that each individual laboratory performs oxygenscan measurements at a standardized time point.
From a practical point of view storing samples overnight before measurements would be the preferred option, allowing for shipment of samples from other hospitals.
F I G U R E 1
Lorrca settings and sample handling influences key oxygenscan measurements EImax, PoS and EImin. (A) RBCs of an untreated patient with HbSS (n = 1), on hydroxyurea (n = 7), on chronic transfusion therapy (n = 9), on HU and transfusion (n = 11) and 2 patients with hemoglobin SC, were measured within 4 hours after blood collection (stored at room temperature) and after 24 hours (stored at 4°C). Maximum deformability (EImax) was significantly higher when measured after 24 hours; (B) Point of Sickling (PoS) showed no difference; (C) Deformability after deoxygenation (EImin) did also not differ; (D) Different amounts of RBCs of untreated HbSS patients (n = 4), on hydroxyurea (n = 5), on chronic transfusion therapy (n = 4), on HU and transfusion (n = 3), and 1 HbSC patient and 1 HbS/δ-thal patient were measured. EImax did not vary; (E) PoS was significantly lower when the amount of RBCs used for the oxygenscan are low (25*10 6 RBCs/mL PVP) compared to reference RBC count (40*10 6 RBCs/mL PVP); (F) EImin was significantly higher with low RBC count; (G) Adjusting the size of the diffraction pattern by changing the gain (401 increases the pattern, while 301 makes the pattern smaller) only significantly affects EImax. This was investigated with RBCs of six HbSS patients (two treated with HU, three with transfusion, and one untreated) and three HbSC patients; (H) The PoS did not differ when the gain was changed, whilst individual values are different depending on genotype and treatment; (I) EImin did not differ whilst individual values are different depending on genotype and treatment; (J) The PI control permits slower deoxygenation, adjusting its speed to the individual patient RBCs. This was investigated in seven HbSS patients (three treated with HU, three with transfusion, and pne untreated) and two HbSC patients. EImax was not different; (K) The PoS showed now difference; (L) EImin was higher when PI control is used, especially in SCD patients on transfusion therapy and HbSC patients. HU, hydroxyurea, Tf, transfusion, w/o, without. PI contr., proportional integral control. Bars represent means, error bars represent SD. ****P < .0001, *P < .05
Our study also demonstrates that speed of deoxygenation and camera gain are important methodological parameters that influence outcome parameters of the oxygenscan module of the Lorrca. Regardless of the choice of settings we recommend that users control these methodological factors strictly in order to ensure correct interpretation of results.
We strongly believe that standardization of oxygenscan measurements will enable comparisons as well as collaborations between the different laboratories studying RBC rheology in SCD. This is particularly important now given the high number of new therapies that are currently being developed for SCD. Thus, standardized oxygenscan measurements have the potential to become an important tool in the evaluation of new treatment strategies, personalized medicine and the prediction of complications in SCD.
Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma
To the Editor:
Daratumumab is a humanized immunoglobulin (IgG-κ) that targets CD38 expressed on plasma cells. It is effective for the treatment of multiple myeloma (MM) in the relapsed/refractory setting and data is emerging to show its efficacy as part of induction therapy for newly diagnosed MM patients.
Hematopoietic stem cells (HSCs) have been shown to express CD38 on the cell surface. Therefore during mobilization there is a theoretical risk of circulating daratumumab binding to and having downstream effects on these cells. There is limited data in the literature on the potential impact of daratumumab on stem cell mobilization and post transplant outcomes, in patients receiving the drug prior to autologous stem cell transplant (ASCT).
In the Cassiopeia trial, 1 patients who received daratumumab in combination with bortezomib, thalidomide, and dexamethasone required more plerixafor and had a lower median number of collected and infused stem cells, compared to patients who did not receive daratumumab. However, data on engraftment is not available. Also, it is not clear if daratumumab used in combination with lenalidomide, a drug shown to impact stem cell mobilization, would affect the overall outcomes.
We conducted a retrospective review of myeloma patients treated with daratumumab, prior to stem cell collection and ASCT, to identify any effects daratumumab therapy may have on the efficacy of the stem cells in bone marrow recovery. The study was conducted at Mayo Clinic Rochester from February 2018 to May 2019, and it was approved by the Mayo Clinic Institutional Review Board. Categorization of high risk cytogenetic abnormalities was according to the International Myeloma Working Group (IMWG) definition and included deletion (17p), t(4;14) and t(14;16). 2 Risk stratification was according to the International Staging System (ISS) and the Revised International Staging System (R-ISS). 2, 3 Granulocyte colonystimulating factor was the preferred agent used for stem cell mobilization,
